Comprehensive analysis of prognosis-related alternative splicing events in ovarian cancer

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Maringe C, Walters S, Butler J, et al. Stage at diagnosis and ovarian cancer survival: evidence from the international cancer benchmarking partnership. Gynecol Oncol. 2012;127(1):75–82.
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304.
   PubMed Web of Science ®Google Scholar
• James NE, Miller K, LaFranzo N, et al. Immune modeling analysis reveals immunologic signatures associated with improved outcomes in high grade serous ovarian cancer. Front Oncol. 2021;11:622182.
   PubMed Web of Science ®Google Scholar
• Li L, Gu H, Chen L, et al. Integrative network analysis reveals a microRNA-Based signature for prognosis prediction of epithelial ovarian cancer. Biomed Res Int. 2019;2019:1056431.
   PubMed Web of Science ®Google Scholar
• Liang H, Bai Y, Wang H, et al. Identification of LncRNA prognostic markers for ovarian cancer by integration of co-expression and CeRNA Network. Front Genet. 2020;11:566497.
   PubMed Web of Science ®Google Scholar
• Hua JT, Ahmed M, Guo H, et al. Risk SNP-Mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19. Cell. 2018;174(3):564–575 e518.
   PubMed Web of Science ®Google Scholar
• Liu H, Gong Z, Li K, et al. SRPK1/2 and PP1alpha exert opposite functions by modulating SRSF1-guided MKNK2 alternative splicing in colon adenocarcinoma. J Exp Clin Cancer Res. 2021;40(1):75.
   PubMed Web of Science ®Google Scholar
• Yin H, Wang J, Li H, et al. Extracellular matrix protein-1 secretory isoform promotes ovarian cancer through increasing alternative mRNA splicing and stemness. Nat Commun. 2021;12(1):4230.
   PubMed Web of Science ®Google Scholar
• Climente-Gonzalez H, Porta-Pardo E, Godzik A, et al. The functional impact of alternative splicing in cancer. Cell Rep. 2017;20(9):2215–2226.
   PubMed Web of Science ®Google Scholar
• Li ZX, Zheng ZQ, Wei ZH, et al. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment. Theranostics. 2019;9(25):7648–7665.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu X, Li J, et al. Comprehensive characterization of alternative splicing in renal cell carcinoma. Brief Bioinform. 2021;22(5). DOI:10.1093/bib/bbab084.
   Web of Science ®Google Scholar
• Du JX, Luo YH, Zhang SJ, et al. Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1. J Exp Clin Cancer Res. 2021;40(1):171.
   PubMed Web of Science ®Google Scholar
• Pellarin I, Dall’Acqua A, Gambelli A, et al. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity. Oncogene. 2020;39(22):4390–4403.
   PubMed Web of Science ®Google Scholar
• Xie R, Chen X, Cheng L, et al. NONO inhibits lymphatic metastasis of bladder cancer via alternative splicing of SETMAR. Mol ther. 2021;29(1):291–307.
   PubMed Web of Science ®Google Scholar
• Bernard A, Hibos C, Richard C, et al. The tumor microenvironment impairs Th1 IFNgamma secretion through alternative splicing modifications of Irf1 Pre-mRNA. Cancer Immunol Res. 2021;9(3):324–336.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang HT, Kadash-Edmondson K, et al. Regional variation of splicing QTLs in human brain. Am J Hum Genet. 2020;107(2):196–210.
   PubMed Web of Science ®Google Scholar
• Guo Z, Zhu H, Xu W, et al. Alternative splicing related genetic variants contribute to bladder cancer risk. Mol Carcinog. 2020;59(8):923–929.
   PubMed Web of Science ®Google Scholar
• Zhang F, Wang H, Yu J, et al. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM. Mol Cancer. 2021;20(1):6.
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang R, Li X, et al. Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B. J Clin Invest. 2019;129(2):676–693.
   PubMed Web of Science ®Google Scholar
• Piva F, Giulietti M, Burini AB, et al. SpliceAid 2: a database of human splicing factors expression data and RNA target motifs. Hum Mutat. 2012;33(1):81–85.
   PubMed Web of Science ®Google Scholar
• Tian J, Wang Z, Mei S, et al. CancerSplicingQTL: a database for genome-wide identification of splicing QTLs in human cancer. Nucleic Acids Res. 2019;47(D1):D909–D916.
   PubMed Web of Science ®Google Scholar
• Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 2009;37:W600–605.
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, et al. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955–961.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Van Allen EM, Omberg L, et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 2014;32(7):644–652.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal ACS. CA: a cancer journal for clinicians. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii61–viii65.
   PubMedGoogle Scholar
• Rahman MA, Krainer AR, Abdel-Wahab O. SnapShot: splicing alterations in cancer. Cell. 2020;180(1):208–208 e201.
   PubMed Web of Science ®Google Scholar
• Nie H, Huang PQ, Jiang SH, et al. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer. Theranostics. 2021;11(8):3898–3915.
   PubMed Web of Science ®Google Scholar
• Belluti S, Semeghini V, Rigillo G, et al. Alternative splicing of NF-YA promotes prostate cancer aggressiveness and represents a new molecular marker for clinical stratification of patients. J Exp Clin Cancer Res. 2021;40(1):362.
   PubMed Web of Science ®Google Scholar
• Liu Z, Sun L, Cai Y, et al. Hypoxia-Induced Suppression of Alternative Splicing of MBD2 Promotes Breast Cancer Metastasis via Activation of FZD1. Cancer Res. 2021;81(5):1265–1278.
   PubMed Web of Science ®Google Scholar
• Shen S, Wang G, Zhang R, et al. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer. EBioMedicine. 2019;40:318–326.
   PubMed Web of Science ®Google Scholar
• Yeong J, Lim JCT, Lee B, et al. High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer. Front Immunol. 2018;9:1209.
   PubMed Web of Science ®Google Scholar
• Liu R, Liao YZ, Zhang W, et al. Relevance of immune infiltration and clinical outcomes in pancreatic ductal adenocarcinoma subtypes. Front Oncol. 2020;10:575264.
   PubMed Web of Science ®Google Scholar
• Bi X, Lou P, Song Y, et al. Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway. Oncogene. 2021;40(29):4832–4845.
   PubMed Web of Science ®Google Scholar
• Chen HY, Wang ML, Laurent B, et al. Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2. Theranostics. 2020;10(1):201–217.
   PubMed Web of Science ®Google Scholar
• Lin JC, Tsai JT, Chao TY, et al. Musashi-1 enhances glioblastoma migration by promoting ICAM1 translation. Neoplasia. 2019;21(5):459–468.
   PubMed Web of Science ®Google Scholar
• Chen H, Liu J, Wang H, et al. Inhibition of RNA-Binding protein Musashi-1 suppresses malignant properties and reverses paclitaxel resistance in ovarian carcinoma. J Cancer. 2019;10(6):1580–1592.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang T, Wu D, et al. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer. J Exp Clin Cancer Res. 2020;39(1):203.
   PubMed Web of Science ®Google Scholar
• Huang W, Li Y, Zhang C, et al. IGF2BP3 facilitates cell proliferation and tumorigenesis via modulation of JAK/STAT signalling pathway in human bladder cancer. J Cell Mol Med. 2020;24(23):13949–13960.
   PubMed Web of Science ®Google Scholar
• Jiang L, Li Y, He Y, et al. Knockdown of m6A reader IGF2BP3 inhibited hypoxia-induced cell migration and angiogenesis by regulating hypoxia inducible factor-1alpha in stomach cancer. Front Oncol. 2021;11:711207.
   PubMed Web of Science ®Google Scholar
• Tran TM, Philipp J, Bassi JS, et al. The RNA-binding protein IGF2BP3 is critical for MLL-AF4-mediated leukemogenesis. Leukemia. 2022;36(1):68–79.
   PubMed Web of Science ®Google Scholar
• Xu Y, Guo Z, Peng H, et al. IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma. J Cell Mol Med. 2022;26(2):410–421.
   PubMed Web of Science ®Google Scholar
• Palanichamy JK, Tran TM, Howard JM, et al. RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. J Clin Invest. 2016;126(4):1495–1511.
   PubMed Web of Science ®Google Scholar
• Huang H, Weng H, Sun W, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285–295.
   PubMed Web of Science ®Google Scholar
• Liu H, Zeng Z, Afsharpad M, et al. Overexpression of IGF2BP3 as a potential oncogene in ovarian clear cell carcinoma. Front Oncol. 2019;9:1570.
   PubMed Web of Science ®Google Scholar